Oklahoma ACE: Molecular Deconstruction of Autoimmune Disease to Aid Clinical Trial Success
俄克拉荷马州 ACE:自身免疫性疾病的分子解构有助于临床试验的成功
基本信息
- 批准号:10608163
- 负责人:
- 金额:$ 8.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-05-01 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:AccelerationAddressAge YearsAnimal ModelAutoantibodiesAutoimmune DiseasesAutoimmune ProcessAutoimmunityB cell therapyB-Cell ActivationB-LymphocytesBasic ScienceBiologicalBiological TestingBiologyCause of DeathCellsCellular Indexing of Transcriptomes and Epitopes by SequencingCertificationClinicalClinical InvestigatorClinical ResearchClinical SciencesClinical TrialsCollaborationsCollectionComplexDataDevelopmentDiseaseEducationEnvironmentFDA approvedFlareFosteringFoundationsGene Expression ProfilingGeneticGoalsHeterogeneityHuman ResourcesImmuneImmunologicsImmunologistImmunophenotypingImmunosuppressive AgentsInflammationInflammatoryInjectionsIntramuscularLeadLeadershipLeukocyte ElastaseLupusManuscriptsMediatorMedlone 21MethodologyMolecularMolecular DiseaseNeuromyelitis OpticaOklahomaPaperPathogenesisPathogenicityPathway interactionsPatient-Focused OutcomesPatientsPharmaceutical PreparationsPolypharmacyPopulationPrediction of Response to TherapyProductivityPublicationsRandomizedRelapseResearchResearch InfrastructureResearch PersonnelResistanceRoleRural CommunitySafetyScientistSerologySiteSjogren&aposs SyndromeSteroidsSubgroupSystemic Lupus ErythematosusTacrolimusTestingTherapeuticThrombotic Thrombocytopenic PurpuraTranslationsWomanWorkactive methodalpha 1-Antitrypsinbasebiobankcohortdesigndisabilitydisease heterogeneitydisorder controldrug repurposingeffectiveness evaluationeffectiveness testingefficacy evaluationexperiencefortificationimprovedindexinginnovationinsightminority communitiesmolecular subtypesmonocytemultidisciplinarymycophenolate mofetilneutrophilnovelnovel therapeuticspre-clinicalpredicting responseprogramsprospective testrecruitrelapse riskresponsesingle cell technologysuccesssynergismtargeted treatmenttherapeutic developmenttherapy developmenttrial design
项目摘要
Project Summary
The Oklahoma ACE (OACE) strives to understand the biology of autoimmune diseases through
interdisciplinary, collaborative research that integrates clinical and basic questions. This prior ACE work has
led to 128 publications, including 42 with authors from 2 or more ACEs, leadership of a previous and ongoing
ACE clinical trial and lead or near lead recruitment in three ACE trials while a Basic ACE. We build on this
expertise through this UM1 Clinical ACE submission. Although significant progress in unveiling mechanisms of
autoimmune disease pathogenesis has been made, development of targeted therapies is critically lacking. For
autoimmune disease therapeutic development to succeed and patient outcomes to improve, deepened
understanding of molecular disease heterogeneity, therapeutic pharmacobiology and improved trial designs
are needed. The Oklahoma ACE will pursue a novel, comprehensive theme of accelerating discovery and
translation by deconstructing molecular heterogeneity to enrich for patients with common molecular pathways,
partnered with repurposed therapies from other fields and novel trial designs which eliminate confounding
background polypharmacy, to address these unmet needs.
Our primary clinical project utilizes our innovative SLE trial design which uses serial depomedrol
injections to suppress disease, halting of background immunosuppressive drugs to provide a more pristine
environment to test the effectiveness of mycophenolate mofetil with or without add-on of tacrolimus to
suppress SLE activity. Partnered mechanistic studies will test our soluble mediator flare index and other select
activated immune cell subsets for the ability to predict upcoming flare, as well as to test specific hypotheses of
MMF response/resistance and of SLE disease flare mechanisms. Preliminary data in our alternate clinical
project has found critical roles of neutrophils in neuromyelitis optica, a complex autoimmune disease where up
to 40% of patients have continual relapse and damage even with treatment with B cell depleting therapies and
steroids. Pre-clinical work from this team has shown efficacy in two animal models of alpha-1 anti-trypsin,
which inhibits neutrophil elastase. This first-in-NMO study will assess effectiveness and safety, as well as
mechanistic studies which test biologic mechanisms of treatment, predictors of response and molecular
mechanisms of NMO flare. Our collaborative project deconstructs molecular heterogeneity and associated
pathogenic mechanisms of disease in subgroups of SLE patients. Building on preliminary data which identifies
seven molecular subsets by gene expression profiling, soluble mediators and autoantibodies, proposed studies
will test hypotheses of specific molecular mechanisms through deep immunophenotyping and single cell
technologies such as scRNAseq, CITE-seq, CyTOF and ChipCytometry. These projects, facilitated by our
Admin Core, will study fundamental aspects of autoimmunity and conduct focused clinical trials for SLE, NMO
and other autoimmune diseases. Our Center will also continue to collaborate and recruit for the ACE Network.
项目摘要
俄克拉荷马州ACE(OACE)致力于了解自身免疫性疾病的生物学,
跨学科的合作研究,整合临床和基础问题。ACE的这一前期工作
导致128篇出版物,其中42篇作者来自2个或更多ACE,领导了以前和正在进行的
ACE临床试验和三项ACE试验中的电极导线或近电极导线招募,而基础ACE。我们以此为基础
通过本次UM 1临床ACE提交的专业知识。虽然在揭示联合国系统的机制方面取得了重大进展,
自身免疫性疾病的发病机制已经确定,靶向治疗的发展是严重缺乏。为
自身免疫性疾病的治疗发展取得成功,患者的结局得到改善,
了解分子疾病异质性、治疗药物生物学和改进试验设计
是必要的。俄克拉荷马州ACE将追求一个新颖的,全面的主题,加速发现,
翻译通过解构分子异质性来富集患者共有的分子通路,
与来自其他领域的重新设计的疗法和消除混淆的新颖试验设计合作
背景多药疗法,以解决这些未满足的需求。
我们的主要临床项目利用我们创新的SLE试验设计,使用连续的地普美醇
注射抑制疾病,停止背景免疫抑制药物,以提供更原始的
环境,以测试霉酚酸酯与或不与他克莫司添加的有效性,
抑制SLE活性。合作机制研究将测试我们的可溶性介质耀斑指数和其他选择
激活免疫细胞亚群的能力,以预测即将到来的耀斑,以及测试特定的假设,
MMF反应/耐药性和SLE疾病发作机制。我们的替代临床试验的初步数据
一个项目发现了嗜中性粒细胞在视神经肌萎缩症中的关键作用,这是一种复杂的自身免疫性疾病,
-40%的患者即使用B细胞耗竭疗法治疗也有持续复发和损伤,
类固醇.该团队的临床前工作已经在两种α-1抗胰蛋白酶动物模型中显示出疗效,
其抑制中性粒细胞弹性蛋白酶。这项首次在NMO的研究将评估有效性和安全性,以及
机制研究,测试治疗的生物学机制、反应的预测因子和分子生物学机制。
NMO耀斑机制我们的合作项目解构分子异质性和相关的
SLE患者亚群的致病机制。根据初步数据,
通过基因表达谱、可溶性介质和自身抗体,拟定研究的7个分子亚组
将通过深层免疫表型和单细胞检测来检验特定分子机制的假设。
技术如scRNAseq、CITE-seq、CyTOF和ChipCytometry。这些项目由我们的
管理核心,将研究自身免疫的基本方面,并为SLE,NMO进行重点临床试验
和其他自身免疫性疾病。我们的中心也将继续合作,并为ACE网络招募。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JUDITH A JAMES其他文献
JUDITH A JAMES的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JUDITH A JAMES', 18)}}的其他基金
Autoimmune Drivers and Protectors Team Science (ADAPTS)
自身免疫驱动器和保护器团队科学 (ADAPTS)
- 批准号:
10657232 - 财政年份:2023
- 资助金额:
$ 8.74万 - 项目类别:
Environmental Influences Driving Autoimmunity and Autoimmune Disease in Tribal Members
环境影响导致部落成员发生自身免疫和自身免疫疾病
- 批准号:
10438444 - 财政年份:2022
- 资助金额:
$ 8.74万 - 项目类别:
Environmental Influences Driving Autoimmunity and Autoimmune Disease in Tribal Members
环境影响导致部落成员发生自身免疫和自身免疫疾病
- 批准号:
10707068 - 财政年份:2022
- 资助金额:
$ 8.74万 - 项目类别:
Oklahoma Shared Clinical and Translational Resources
俄克拉荷马州共享临床和转化资源
- 批准号:
10293114 - 财政年份:2021
- 资助金额:
$ 8.74万 - 项目类别:
Oklahoma ACE: Molecular Deconstruction of Autoimmune Disease to Aid Clinical Trial Success
俄克拉荷马州 ACE:自身免疫性疾病的分子解构有助于临床试验的成功
- 批准号:
9901415 - 财政年份:2019
- 资助金额:
$ 8.74万 - 项目类别:
Oklahoma ACE: Molecular Deconstruction of Autoimmune Disease to Aid Clinical Trial Success
俄克拉荷马州 ACE:自身免疫性疾病的分子解构有助于临床试验的成功
- 批准号:
10396550 - 财政年份:2019
- 资助金额:
$ 8.74万 - 项目类别:
Oklahoma ACE: Molecular Deconstruction of Autoimmune Disease to Aid Clinical Trial Success
俄克拉荷马州 ACE:自身免疫性疾病的分子解构有助于临床试验的成功
- 批准号:
10158411 - 财政年份:2019
- 资助金额:
$ 8.74万 - 项目类别:
Oklahoma Rheumatic Disease Research Cores Center (Overall Application)
俄克拉荷马州风湿病研究核心中心(整体申请)
- 批准号:
10478206 - 财政年份:2018
- 资助金额:
$ 8.74万 - 项目类别:
Oklahoma Rheumatic Disease Research Cores Center
俄克拉荷马州风湿病研究核心中心
- 批准号:
10704387 - 财政年份:2018
- 资助金额:
$ 8.74万 - 项目类别:
Molecular Phenotyping of Autoimmunity in Tribal Members: Aiding Precision Medicine and Tribal Student Training
部落成员自身免疫的分子表型:协助精准医学和部落学生培训
- 批准号:
10005381 - 财政年份:2018
- 资助金额:
$ 8.74万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 8.74万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 8.74万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 8.74万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 8.74万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 8.74万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 8.74万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 8.74万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 8.74万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 8.74万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 8.74万 - 项目类别:
Research Grant